SEC Form 4 · accession 0001193125-26-380404
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kristin Abate
Officer — Chief Accounting Officer
Period of report
Sep 1, 2026
Accepted (ET)
Sep 2, 2026 · 4:57 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001503802
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2026 | S | 19 | $2.02 | D | 23,782 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.